No Data
No Data
No Data
No Data
No Data
Press Release: Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Company to present an update of its ongoing
Dow JonesApr 24 10:05 ET
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
First Data Demonstrating Application of PREDATOR Platform in Immune-Mediated Diseases WATERTOWN, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (
GlobeNewswireApr 23 08:00 ET
Buy Rating Affirmed for Werewolf Therapeutics on Promising PREDATOR Platform Prospects and Strong Pipeline Potential
TipRanksApr 19 10:06 ET
All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy
Yahoo FinanceApr 15 12:00 ET
Institutional Owners May Ignore Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Recent US$53m Market Cap Decline as Longer-term Profits Stay in the Green
Key Insights Institutions' substantial holdings in Werewolf Therapeutics implies that they have significant influence over the company's share price 50% of the business is held by the top 6 sharehol
Simply Wall StApr 13 10:39 ET
Analysts Are Bullish on Top Healthcare Stocks: Lucid Diagnostics (LUCD), Werewolf Therapeutics (HOWL)
TipRanksApr 10 13:50 ET
No Data
No Data
BelleWeather : I’ve also got this one on my watchlist:)
TrytosaveabitOP BelleWeather: Fantastic! I hope you’re having a great and restful weekend! Back to account building tomorrow! GL!